Collaborative Work can Lead to Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Collaborative Work can Lead to Innovation


Pharmaceutical Technology Europe
Volume 24, Issue 9


Dr. Ralf Fink
Dear Reader,
In drug development, the majority of new chemical entities are lipophilic and/or poorly soluble. New actives often fail during development due to these challenging properties. The solubilization of actives is therefore an important approach towards improving the bioavailability of a drug molecule in an accepted dosage form.

In this special issue, BASF would like to open up a discussion about solubilization challenges and innovative solutions, focusing on both products and cost-effective production technologies, such as hot-melt extrusion and spray drying. Because innovation is always the result of many, companies such as Catalent, Bend Research and Johnson & Johnson have also contributed with their expertise on this topic.

True to its legacy of innovation, BASF continues to develop new innovative solubilizers, such as Soluplus®. Thus, together with our established portfolio of Kolliphor® solubilizers and Kollisolv® cosolvents, we offer a versatile toolbox capable of coping with the many solubilization challenges facing our industry. This, in combination with our SoluHTS® screening robot, enables the industry to screen and identify the most suitable solubilization excipients faster, thereby shortening their product development time.

In the end, there is no single way out of the "maze of pharmaceutical development." However, the use of new technologies and innovative products may get us out quicker.

Dr. Ralf Fink

Vice-President of Global Marketing,
BASF Pharma Ingredients & Services

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here